Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.

Bone Marrow Aspirate

Abhishek Tripathi, MD

The purpose of this research is to collect health-related information as well as bone marrow and blood specimens to determine if a new form of treatment for patients with kidney and bladder cancer may be possible.

This research will collect specimens from the bone marrow and blood to determine if a new treatment for kidney or bladder cancer may be possible. This research study will collect a bone marrow sample as well as a blood sample.

Participation in the research study will last approximately 60 days which includes time to determine if the patient is eligible to participate in the study, perform the research procedures and follow-up with the patient following the research procedures to determine if they are experiencing any side effects. Participation will end approximately 30 days following the bone marrow collection.

The bone marrow and blood samples will be collected from all patients in both cohorts only at a single time point, after they have been enrolled on the study.

Patients enrolled on this study in either the Renal Cell Carcinoma cohort or the Urothelial Carcinoma cohort will undergo the same procedures of bone marrow aspiration and blood draw.

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell Carcinoma and Urothelial Carcinoma

A successful expansion will be greater than or equal to 50% viable and greater than or equal to 50% CD3 positive.

WindMIL Therapeutics

University of Oklahoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma	NCT04341740	Renal Cell Carc... Urothelial Carc...	Bone Marrow Asp...	18 Years -	University of Oklahoma
Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma	NCT04341740	Renal Cell Carc... Urothelial Carc...	Bone Marrow Asp...	18 Years -	University of Oklahoma

Spots Global Cancer Trial Database for marrow infiltrating lymphocytes